- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Clovis' Shares Soar Following Data Released from Ovarian Cancer Trial
Thanks to new data from its Phase 3 Trial Clovis Oncology saw a 50 percent increase in its stock on Monday (June 19)
Clovis Oncology (NASDAQ:CLVS) started the week off with a bang when it released new data from its ARIEL3 phase 3 trial of rucaparib, a small molecule inhibitor being developed in ovarian cancer and other solid tumor indications. The company’s stock saw an increase of 50 percent early on Monday (June 19).
The trial enrolled 564 women who had platinum-sensitive, high-grade ovarian, fallopian tube, or primary peritoneal cancer. The trial met its endpoint of improved progression-free survival (PFS) thanks to better results from rucaparib compared with a placebo.
At the end of last week’s trading period, Clovis Oncology closed at a price of $59.97; on Monday, the stock opened the market at $89.65. This increase no doubt provides a boost to the company’s stock price, soaring 103.2 percent year-to-date.
The Colorado-based company revealed–based on the new data–that it will be applying for a supplemental New Drug Application (sNDA) within the next four months for a “maintenance treatment indication for all women with platinum-sensitive ovarian cancer” who responded well to the therapy.
Clovis may bring new option for women fighting ovarian cancer
Patrick Mahaffy, president and CEO of Clovis Oncology, said in the release that the company was excited with the positive results demonstrated in this test, as it provides a potential new tool for women battling ovarian cancer.
“[R]ucaparib demonstrates a clinically meaningful impact in delaying disease recurrence in women in this trial with advanced ovarian cancer,” principal investigator for the study Dr. Robert Coleman said in the statement.
Dr. Coleman added the results were promising because it proposed “women are able to stay on rucaparib for a prolonged period of time while gaining benefit.”
The company indicated Rucaparib can target mutant BRCA tumors and “other DNA repair deficiencies beyond BRCA.”
Mahaffy told Reuters 25 percent of the projected 22,400 diagnoses of ovarian cancer this year will have BRCA mutations, which can increase the probability of getting ovarian cancer.
According to the data, the company’s treatment provided 10.8 months as a median where the disease wouldn’t get worse, compared to 5.4 months for the women in trial receiving a placebo.
Investor Takeaway
This is a success story for Clovis and further proves the make or break factor from trial results and their power in the market.
Leerink analyst Michael Schmidt told MarketWatch the results from Clovis were “particularly impressive” compared to the data from other competitors, like Tesaro (NASDAQ:TSRO) and AstraZeneca (NYSE:AZN) with similar cancer drugs.
“If approved, Rubraca would have the broadest label of any PARP inhibitor in ovarian cancer… which we think should bode well for the commercial uptake of the drug,” Schmidt said.
Don’t forget to follow us @INN_LifeScience for real-time news updates.
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.